LGT 209

Drug Profile

LGT 209

Alternative Names: Anti-PCSK9 monoclonal antibody - Novartis; LGT209; NVP-LGT 209

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 24 Aug 2016 Cyon Therapeutics in-licenses LGT 209 for the use systemic inflammatory response syndrome and the prevention and treatment of sepsis from Novartis
  • 24 Aug 2016 Cyon Therapeutics plans a phase II trial for Sepsis in
  • 23 Jan 2013 Discontinued - Phase-II for Hypercholesterolaemia in USA (IV, SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top